Daiichi Sankyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report
SynopsisDaiichi Sankyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.
Summary
- Detailed information on Daiichi Sankyo Co., Ltd. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Daiichi Sankyo Co., Ltd. in the form of a SWOT analysis
- An in-depth view of the business model of Daiichi Sankyo Co., Ltd. including a breakdown and examination of key business segments
- Intelligence on Daiichi Sankyo Co., Ltd.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Daiichi Sankyo Co., Ltd., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons To Buy
- Gain understanding of Daiichi Sankyo Co., Ltd. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Daiichi Sankyo Co., Ltd. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Daiichi Sankyo Co., Ltd.'s business structure, strategy and prospects.
Key Highlights
Daiichi Sankyo Co., Ltd. (Daiichi Sankyo or 'the group') is a Japan-based holding company primarily engaged in the manufacture and sales of pharmaceuticals. It operates in Asia, Europe and the Americas. The group is headquartered in Tokyo, Japan.
Daiichi Sankyo is engaged in the research and development, manufacture, sales, and marketing of pharmaceutical products. Co. operates its operation in Japan, the Americas, Europe, China and Asia. Co. provides ethical pharmaceutical and proprietary drugs. Co.'s principal products include antihypertensive agent "Olmetec" ("Olmesartan" in overseas), ulcer treatment drug "NEXIUM," Alzheimer's disease treatment "Memary," anti-influenza treatment "Inavir," antiplatelet agent "Prasugrel," anticoagulant "Edoxaban," anti-inflammatory analgesic "Loxonin" Tape, synthetic antibacterial agent "Cravit," treatment for bone complications "RANMARK," and anticoagulant "LIXIANA."
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.